{
  "trial_id": "NCT02390050",
  "trial_group": "diabetes",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, sex, body mass index (BMI), HbA1c levels, treatment status (treatment na\u00efve or on one oral anti-diabetic medication), blood pressure, lipid levels, estimated glomerular filtration rate (eGFR), liver function tests (ALT, AST, total bilirubin), fasting plasma glucose, urine albumin-to-creatinine ratio (UACR), history of hypertension, history of hyperlipidemia, history of genitourinary infections, history of cardiovascular events (myocardial infarction, unstable angina, stroke, heart failure), hepatitis B surface antigen status, hepatitis C status, drug abuse screen results, HIV status, life expectancy, history of investigational drug treatment, prior use of SGLT2 inhibitors, compliance with study medication.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "BMI",
          "body mass index (BMI)"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Region of Enrollment",
        "Height",
        "Body Weight"
      ],
      "remaining_candidate_features": [
        "HbA1c levels",
        "treatment status (treatment na\u00efve or on one oral anti-diabetic medication)",
        "blood pressure",
        "lipid levels",
        "estimated glomerular filtration rate (eGFR)",
        "liver function tests (ALT, AST, total bilirubin)",
        "fasting plasma glucose",
        "urine albumin-to-creatinine ratio (UACR)",
        "history of hypertension",
        "history of hyperlipidemia",
        "history of genitourinary infections",
        "history of cardiovascular events (myocardial infarction, unstable angina, stroke, heart failure)",
        "hepatitis B surface antigen status",
        "hepatitis C status",
        "drug abuse screen results",
        "HIV status",
        "life expectancy",
        "history of investigational drug treatment",
        "prior use of SGLT2 inhibitors",
        "compliance with study medication."
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Body Mass Index, Baseline HbA1c, Duration of Diabetes, Blood Pressure, Fasting Plasma Glucose, eGFR, Use of Anti-diabetic Medication,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "BMI",
          "Body Mass Index"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Height",
        "Body Weight"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Baseline HbA1c",
        "Duration of Diabetes",
        "Blood Pressure",
        "Fasting Plasma Glucose",
        "eGFR",
        "Use of Anti-diabetic Medication"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Diabetes Diagnosis Duration, Body Mass Index, HbA1c, Fasting Plasma Glucose, Systolic Blood Pressure, Diastolic Blood Pressure, eGFR, History of Hypertension, History of Hyperlipidemia.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "BMI",
          "Body Mass Index"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Height",
        "Body Weight"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Diabetes Diagnosis Duration",
        "HbA1c",
        "Fasting Plasma Glucose",
        "Systolic Blood Pressure",
        "Diastolic Blood Pressure",
        "eGFR",
        "History of Hypertension",
        "History of Hyperlipidemia"
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, body mass index (BMI), duration of type 2 diabetes mellitus, HbA1c at screening, fasting plasma glucose at screening, systolic blood pressure, diastolic blood pressure, estimated glomerular filtration rate (eGFR), history of hypertension, history of hyperlipidemia, use of oral anti-diabetic medication, use of medication for hypertension or hyperlipidemia.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "ethnicity"
        ],
        [
          "BMI",
          "body mass index (BMI)"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Region of Enrollment",
        "Height",
        "Body Weight"
      ],
      "remaining_candidate_features": [
        "duration of type 2 diabetes mellitus",
        "HbA1c at screening",
        "fasting plasma glucose at screening",
        "systolic blood pressure",
        "diastolic blood pressure",
        "estimated glomerular filtration rate (eGFR)",
        "history of hypertension",
        "history of hyperlipidemia",
        "use of oral anti-diabetic medication",
        "use of medication for hypertension or hyperlipidemia."
      ]
    }
  }
}